Related by context. All words. (Click for frequent words.) 65 PS# [001] 62 Chemophase 62 INCB# [001] 62 Symadex 61 Traficet EN 61 RDEA# 61 ganetespib 60 orally bioavailable 60 eniluracil 60 Phase 2a trial 60 Carfilzomib 60 AEG# 60 antiviral activity 60 oral prodrug 60 dose cohorts 60 ISTODAX 60 PXD# 60 pharmacokinetic profile 60 torezolid phosphate 60 velafermin 60 Azedra 60 Phase 1b 59 PRT# 59 HGS ETR1 59 favorable pharmacokinetic profile 59 CBLB# 59 XmAb# 59 Triolex 59 radezolid 59 systemically administered 59 SCH # 59 #ME# 59 administered subcutaneously 59 OXi# 59 Sym# 59 MGd 59 CR# vcMMAE 59 APOPTONE 59 BAY #-# 59 YONDELIS 59 CIMZIA TM 59 VAPRISOL 59 pharmacodynamic profile 59 HspE7 59 Amigal 58 alvespimycin 58 IRX 2 58 TRIOLEX 58 Xanafide 58 MGCD# [001] 58 CYT# 58 Phase Ib study 58 forodesine 58 maximally tolerated dose 58 rFIXFc 58 CEQ# 58 HuMax EGFr 58 C1 INH 58 edoxaban 58 GRN#L 58 GLP toxicology studies 58 Perifosine 58 ALN TTR# 58 PEG Interferon lambda 58 Phase 2a 58 intranasal delivery 58 oral rivaroxaban 58 HCV protease 58 oral dosing 58 NGX# 58 CoFactor 58 preclinically 58 phase Ib 58 OncoVEX GM CSF 58 fosbretabulin 58 HuMax CD4 58 pharmacokinetic PK 58 DermaVir Patch 58 TPI ASM8 58 Phase Ib 58 dosage regimens 57 HGS ETR2 57 Omacetaxine 57 PRTX 57 pharmacokinetic PK study 57 ISIS # 57 pharmacokinetic 57 dose escalation 57 TRO# 57 obatoclax 57 Panzem R NCD 57 isatoribine 57 anti leukemic 57 dose cohort 57 ascending doses 57 CA4P 57 DAVANAT 57 Aclidinium 57 Bortezomib 57 delafloxacin 57 anticancer activity 57 Tekamlo 57 rHuPH# 57 DP b# 57 posaconazole 57 Valortim ® 57 MBP# [001] 57 Zerenex 57 oritavancin 57 Sapacitabine 57 voreloxin 57 RSD# 57 Tyrima 57 Androxal TM 57 INT# [002] 57 TELINTRA 57 riociguat 57 JANUVIA 57 CCR5 antagonist 57 CBLC# 57 MNTX 57 Androxal 57 CCX# 57 huC# DM4 57 PEG PAL 57 Plicera 57 PCK# 57 dosing cohort 57 GAMMAGARD 56 eltrombopag 56 nitazoxanide 56 tolerability profile 56 tezampanel 56 IAP inhibitor 56 LT NS# 56 Golimumab 56 pharmacodynamic PD 56 R#/MEM # 56 tolerability 56 CTAP# Capsules 56 bavituximab 56 Omacetaxine mepesuccinate 56 eculizumab 56 PEG SN# 56 HQK 56 tgAAC# 56 Ophena TM 56 docetaxel Taxotere R 56 thymalfasin 56 bronchodilation 56 JVRS 56 synthetic retinoid 56 Solulin 56 diabetic neuropathic pain 56 dose limiting toxicities 56 deforolimus 56 BAL# [002] 56 DAS# [001] 56 MEK inhibitors 56 pharmacokinetic PK profile 56 EOquin TM 56 Multimeric 56 idarubicin 56 AVE# 56 DU #b 56 dosing regimens 56 IMGN# 56 Dasatinib 56 teriflunomide 56 ON #.Na 56 Phase 1b trial 56 dosing cohorts 56 subcutaneous SC 56 otelixizumab 56 alkylating agent 56 active comparator 56 AZX# 56 LEXIVA r 56 nucleotide analog 56 ascending dose 56 GFT# 56 sapacitabine 56 PSN# [002] 56 NP2 Enkephalin 56 Exherin TM 56 LEP ETU 56 antitumor activity 55 fluticasone furoate 55 liposomal formulation 55 calcitonin 55 brivaracetam 55 analgesic efficacy 55 subcutaneous injections 55 Synavive 55 enzastaurin 55 mg dose 55 Bezielle 55 plasma kallikrein inhibitor 55 antiviral efficacy 55 NXL# 55 hyperphenylalaninemia HPA due 55 LEVADEX 55 subcutaneously administered 55 nucleoside analog 55 tolerability profiles 55 Teriflunomide 55 milatuzumab 55 highly immunogenic 55 decitabine 55 Reolysin 55 ARIKACE 55 VP# [004] 55 histone deacetylase HDAC inhibitor 55 pharmacodynamic properties 55 phase 2a 55 GSK# [001] 55 CANCIDAS 55 ANAVEX #-# [003] 55 Tarvacin TM 55 Imprime PGG 55 Phase 1a 55 sitagliptin 55 GLYX 55 ELND# 55 Darinaparsin 55 CIMZIA ™ 55 AP# [003] 55 Phase 2a clinical 55 preclinical efficacy 55 Menerba 55 viral kinetic 55 Valortim 55 Allovectin 7 ® 55 R baclofen 55 Onconase 55 Phase #b/#a trial 55 phase IIb clinical 55 PI3K inhibitor 55 metaglidasen 55 systemic absorption 55 HGS# 55 interferon alfa 2b 55 itraconazole 55 tezampanel NGX# 55 Preclinical studies 55 Phase #/#a trial 55 Phase 2b study 55 lomitapide 55 Panzem R 55 Phase #b/#a 55 RLY# 55 OMP #M# 55 pharmacokinetic properties 55 Alpharadin 55 depsipeptide 55 urocortin 2 55 vorinostat 55 TG# [003] 55 TRV# [001] 55 ATL# [001] 55 mertansine 55 dose escalation Phase 55 raltegravir 55 ENMD # 55 metreleptin 55 HCD# [002] 55 Archexin 55 Inhalation Solution 55 ANA# 55 Phase Ib II 55 TMC# [002] 55 AMD# [003] 55 HuMax CD# 55 blinded randomized placebo controlled 55 ESBA# 55 S/GSK# 55 mapatumumab 55 Alocrest 55 tanespimycin 55 RGB # 54 Marqibo 54 PREZISTA r 54 PROMACTA 54 pegylated interferon alfa 2a 54 AEGR 54 Pegasys ® 54 preclinical studies 54 visilizumab 54 MEK inhibitor 54 intravesical 54 Altastaph 54 Copegus ribavirin 54 hour bronchodilation 54 ataluren 54 elotuzumab 54 insulin degludec 54 phase IIb trial 54 romidepsin 54 multiple ascending dose 54 Phase IIa trial 54 CORT # 54 pharmacodynamic 54 Dapagliflozin 54 administered orally 54 subcutaneous formulation 54 erlotinib Tarceva ® 54 Proellex TM 54 Phase IIb trials 54 Preclinical studies suggest 54 oral bioavailability 54 BioVant 54 indibulin 54 docetaxel Taxotere ® 54 mGluR5 NAM 54 vidofludimus 54 belinostat 54 GMX# 54 novel prodrug 54 mg kg dose 54 bevirimat 54 vivo efficacy 54 CRMD# 54 #beta estradiol 54 calcineurin inhibitors 54 CLORETAZINE TM VNP#M 54 GHRH 54 EVIZON 54 solithromycin 54 dose escalation trial 54 Tarceva TM 54 imetelstat 54 INCB# [002] 54 arbaclofen 54 evaluating tivozanib 54 aprepitant 54 OncoVEX 54 pharmacodynamics 54 boosted protease inhibitor 54 LEXIVA 54 nelfinavir 54 ritonavir boosted 54 Arikace 54 PROCHYMAL 54 Anthim 54 octreotide 54 SAR# [004] 54 pharmacodynamic effects 54 KNS # 54 adecatumumab 54 lintuzumab 54 Phase IIb trial 54 DCCR 54 Fx #A 54 μg dose 54 Zoraxel 54 AIR# [001] 54 rNAPc2 54 OMNARIS HFA 54 plasma uric acid 54 lixisenatide 54 Valortim R 54 Laquinimod 54 TELCYTA 54 novel VDA molecule 54 Phenoptin 54 amphotericin B 54 immunomodulatory 54 intravenously administered 54 antitumor 53 Mipomersen 53 AQ4N 53 ORMD 53 Phase 2b trial 53 DuraSite 53 Serdaxin 53 granisetron 53 Azixa 53 Interferon alpha 53 relapsed MM 53 polymerase inhibitors 53 Anidulafungin 53 non nucleoside 53 ELACYT 53 Phase IIb clinical trials 53 BAL# [001] 53 peripherally acting 53 Aplidin R 53 TORISEL 53 intravitreal injection 53 NLX P# 53 dose escalation study 53 virus HCV protease inhibitor 53 alagebrium 53 CRx 53 tocilizumab 53 Elvitegravir 53 APTIVUS r 53 Zysolin TM 53 oral antidiabetic 53 pharmacokinetic equivalence 53 active moiety 53 Blinatumomab 53 dose proportional pharmacokinetics 53 caspofungin 53 Phase 1a clinical 53 sorafenib tablets 53 potent antiviral 53 Antiviral Activity 53 xenograft models 53 #mg BID [001] 53 pertuzumab 53 varespladib 53 orally dosed 53 BCX# 53 dose dose escalation 53 cobiprostone 53 busulfan 53 EFAPROXYN 53 rFVIIIFc 53 LY# [003] 53 ALKS 53 dose proportionality 53 pomalidomide 53 histone deacetylase inhibitor 53 nucleoside reverse transcriptase inhibitor 53 docetaxel chemotherapy 53 Phase Ib clinical 53 HDACi 53 blinatumomab 53 dirucotide 53 Debio 53 dosing regimen 53 pegylated 53 eprotirome 53 crizotinib PF # 53 BrachySil 53 pharmacokinetics 53 safety tolerability pharmacokinetics 53 celgosivir 53 lanthanum carbonate 53 orally administered 53 Panzem 53 PD LID 53 pharmacodynamic markers 53 generation purine nucleoside 53 OHR/AVR# 53 Pharmacokinetics PK 53 Ophena 53 beta2 agonist 53 uricase 53 Tamibarotene 53 sorafenib Nexavar 53 dexpramipexole 53 immunomodulator 53 Aplidin 53 SCIg 53 SNT MC# 53 Voreloxin 53 olmesartan 53 Cloretazine R VNP#M 53 pharmacokinetics PK 53 sulodexide 53 CRLX# 53 mcg dose 53 2 methoxyestradiol 53 tolerability pharmacokinetics 53 HIF PH inhibitors 53 relapsed refractory multiple myeloma 53 cannabinor 53 pharmacokinetic parameters 53 oral FTY# 53 ramelteon 53 Plenaxis TM 53 trodusquemine 53 ADAGIO study 53 azacytidine 53 HCV SPRINT 53 cilengitide 53 seliciclib 53 pegylated interferons 53 PDE4 inhibitor 53 MTP inhibitor 53 Darusentan 53 adipiplon 53 selective androgen receptor modulator 53 retaspimycin 53 protease inhibitor PI 53 dasatinib 53 vernakalant hydrochloride 53 DexaSite 53 antithrombotic 53 VA# [002] 53 trabectedin 53 QLT# 53 NOX E# 53 IMC A# 53 pharmacokinetics pharmacodynamics 53 safety tolerability pharmacokinetic 53 PRX # 53 MAGE A3 ASCI 53 valopicitabine 53 Melphalan 53 bolus injection 53 selective modulator 52 PF # [001] 52 synthetic peptide 52 ACTEMRA TM 52 somatostatin analogue 52 dosed orally 52 Empatic 52 IIa trial 52 alvimopan 52 Linaclotide 52 immunological responses 52 axitinib 52 REMICADE ® 52 Raltegravir 52 cytoprotective 52 ZYBRESTAT 52 LY# [002] 52 AeroLEF TM 52 Pivotal Phase III 52 azacitidine 52 investigational protease inhibitor 52 CorVue ™ 52 neratinib 52 HMG CoA reductase inhibitor 52 phase IIa clinical 52 SPRYCEL 52 biodistribution 52 Alzhemed TM 52 tiotropium bromide 52 DXL# 52 Genz # 52 MLN# 52 RG# [001] 52 GAMMAGARD LIQUID 52 AAG geldanamycin analog 52 refractory gout 52 novel histone deacetylase 52 oral ridaforolimus 52 cyclophilin inhibitor 52 AZILECT R 52 JAK inhibitor 52 sunitinib 52 inhibitor RG# 52 TMC# [001] 52 HER2 positive metastatic breast 52 monotherapy 52 erythropoietic 52 oral antiviral 52 piperacillin tazobactam 52 zileuton 52 adalimumab Humira 52 ulimorelin 52 ribavirin RBV 52 Eltrombopag 52 pharmacokinetic profiles 52 apremilast 52 TNFalpha 52 label dose escalation 52 double blinded placebo 52 Oral NKTR 52 EndoTAG TM -1 52 retapamulin 52 6R BH4 52 docetaxel 52 tigecycline 52 nanopharmaceutical 52 Enzastaurin 52 rBChE 52 Liposomal 52 PrevOnco ™ 52 aliskiren 52 ProLindac 52 PYY 52 elagolix 52 teduglutide 52 ongoing Phase 1b 52 ara C 52 Apoptone 52 GAP #B# 52 CDK inhibitor 52 hematologic malignancies 52 angiotensin receptor blocker ARB 52 Ostarine 52 elacytarabine 52 cangrelor 52 Vidofludimus 52 insulin lispro 52 Hyphanox 52 picoplatin 52 antitumor efficacy 52 omega interferon 52 lipid parameters 52 INCB# [003] 52 tolerated dose MTD 52 mycophenolate mofetil 52 teriparatide 52 prodrug 52 ISENTRESS 52 tivozanib 52 ProSavin 52 Fludara 52 #mg dose [001] 52 Cloretazine 52 IDX# 52 RSD# oral 52 XP# Transported Prodrug 52 bovine thrombin 52 Dual Opioid 52 BRIM2 52 immune modulating 52 tolvaptan 52 AZILECT ® 52 tecarfarin 52 pramlintide 52 tacrolimus ointment 52 chemotherapeutic drug 52 intravenous dosing 52 DOXIL 52 Telintra 52 immunogenicity 52 TG# [001] 52 Pemetrexed 52 Q#IR 52 glufosfamide 52 gemcitabine Gemzar 52 Phase IIa 52 antitumor effects 52 TOLAMBA 52 Adalimumab 52 anti amnesic 52 mg TID 52 SRT# [003] 52 Aptivus ® 52 stated Michelle Berrey 52 demonstrated antitumor activity 52 blinded placebo controlled 52 favorable pharmacokinetic 52 cediranib 52 plasma concentrations 52 Kahalalide F 52 antineoplastic 52 INVEGA ® 52 ADVANCE PD 52 kinase inhibitor 52 eliglustat tartrate 51 interferon gamma 1b 51 parathyroid hormone PTH 51 selective inhibitor 51 Actilon 51 prucalopride 51 chlorambucil 51 KRN# 51 mcg kg 51 dose regimens 51 tipranavir 51 intranasal formulation 51 pivotal Phase 51 pharmacokinetic interactions 51 bendamustine 51 IFN beta 51 clinical pharmacology studies 51 Phase IIIb clinical 51 glatiramer acetate 51 clevidipine 51 ZYBRESTAT fosbretabulin 51 APTIVUS 51 interferon beta 51 renal toxicity 51 VNP#M 51 confirmatory Phase III 51 octreotide acetate 51 CG# [003] 51 MIRCERA 51 ALGRX 51 PLX PAD 51 Phase IIa trials 51 anticancer agent 51 phase IIa 51 vismodegib 51 vitro cytotoxicity 51 Capesaris 51 baminercept 51 evaluating REVLIMID 51 EGS# 51 inhaled corticosteroid ICS 51 TLK# 51 avosentan 51 reslizumab 51 multicenter Phase II 51 AZILECT 51 KAPIDEX 51 telaprevir dosing 51 nab paclitaxel 51 LCP Tacro 51 fosamprenavir 51 Dacogen injection 51 mg doses 51 pramlintide metreleptin combination 51 viral kinetics 51 adalimumab 51 nucleoside 51 Vidaza 51 Phase III clinical trials 51 alicaforsen enema 51 hGH CTP 51 Perforomist ™ Inhalation Solution 51 ruxolitinib 51 HDAC Inhibitor 51 Locteron 51 sorafenib Nexavar ® 51 GLP1 agonist 51 ritonavir boosted protease inhibitor 51 Posiphen 51 multicenter Phase III 51 flavopiridol 51 MERLIN TIMI 51 peg IFN 51 HIF PHI 51 phase IIb study 51 Protelos 51 selective inhibition 51 virologic 51 Welchol 51 coadministration 51 pharmacodynamic parameters 51 PEGPH# 51 CTA# 51 selectively inhibits 51 Virulizin ® 51 dosing schedules 51 MoxDuo ® IR 51 Iloperidone 51 MoxDuo IR 51 LibiGel ® 51 nonclinical studies 51 TYGACIL 51 ceftazidime 51 sirolimus 51 mRCC 51 preclinical pharmacokinetic 51 UPLYSO 51 Trofex 51 SNRI 51 myopathy rhabdomyolysis 51 NEBIDO 51 MGCD# [002] 51 resolvin 51 Enhanze Technology 51 AzaSite Plus 51 glycopyrrolate 51 5 HT2C receptor 51 plasma pharmacokinetics 51 investigational drug 51 vitro studies 51 EZN 51 oral deforolimus 51 GATTEX 51 Annamycin 51 telcagepant 51 ARIXTRA 51 antiepileptic drug 51 tipranavir r 51 budesonide foam 51 uric acid lowering 51 galiximab 51 direct thrombin inhibitors 51 Cloretazine ® 51 CTCE 51 iclaprim 51 aclidinium 51 RE SURGE 51 Lp PLA 2 51 denufosol 51 VELCADE 51 oral iron chelator 51 capsule formulation 51 FOSRENOL ® 51 Forodesine HCl 51 rALLy clinical trial 51 bortezomib Velcade 51 EDEMA3 trial 51 Phase #/#a 51 ciclesonide 51 microdose 51 abacavir lamivudine 51 KSP inhibitor 51 heavily pretreated 51 HCV RESPOND 2 51 MYCAMINE 51 SYMBICORT 51 registrational 51 rALLy trial 51 Zavesca R 51 Vidaza azacitidine 51 bosentan 51 glucose lowering 51 clinically meaningful 51 COPEGUS 51 alfa 2a 51 placebo controlled Phase 51 neuroprotective properties 51 cytotoxic 51 certolizumab pegol 51 interferon alfa 51 dose cytarabine 51 Anticalins 51 ATL/TV# 51 Spheramine 51 FOLOTYN ® 51 USL# 51 G CSF 51 Belerofon 51 selective antagonist 51 Phase 2b clinical 50 GetGoal Phase III 50 etanercept 50 insulin glargine 50 trastuzumab DM1 T DM1 50 AEZS 50 secondary efficacy endpoints 50 liprotamase 50 receptor antagonist 50 Vicinium TM 50 peginterferon alfa 2b 50 Tasimelteon 50 triphendiol 50 ADX# 50 vicriviroc 50 Phase 2b randomized 50 peptidomimetic 50 oral methylnaltrexone 50 recurrent genital herpes 50 huN# DM1 50 vivo toxicology 50 anti angiogenic 50 NEUGENE antisense 50 cytochrome P# #A# 50 deferiprone 50 Relivar 50 Phase IIa clinical 50 clinically relevant 50 5 HT2A receptor 50 Phase 1b clinical trials 50 dasatinib Sprycel 50 paclitaxel eluting stents 50 MORAb 50 ORENCIA ® 50 vapreotide acetate 50 masitinib 50 LibiGel Phase III 50 NN# [001] 50 PEARL SC 50 Phase IIB 50 desvenlafaxine succinate 50 certolizumab 50 lopinavir r 50 standard chemotherapy regimen 50 clinically meaningful efficacy 50 motesanib 50 ganaxolone 50 pivotal Phase III 50 perifosine 50 Phase IIA 50 immunomodulatory therapy 50 dose escalation clinical 50 EGFR HER2 50 AZD# 50 MabCampath 50 polymerase inhibitor 50 PPAR gamma agonist 50 #mg dose [003] 50 IFN α 50 dose escalation phase 50 intermittent dosing 50 amprenavir 50 daunorubicin 50 Campath alemtuzumab 50 urate lowering 50 NVA# 50 pharmacodynamics PD 50 methylnaltrexone 50 multicenter randomized placebo controlled 50 elvitegravir 50 mg QD 50 enfuvirtide 50 pharmacokinetic studies 50 mTOR inhibitors 50 cytotoxicity 50 Exelixis compounds 50 amrubicin 50 antiarrhythmic 50 insulin detemir 50 PTH analogue 50 ofatumumab 50 Peginterferon 50 EXPAREL ™ 50 prostanoid 50 ARCOXIA 50 trastuzumab Herceptin ® 50 CaPre TM 50 phase IIb 50 indacaterol 50 zalutumumab 50 thorough QT 50 PHX# 50 VELCADE melphalan 50 sunitinib Sutent ® 50 mg/m2 cohort 50 Phase 1b clinical 50 pegylated interferon alfa 50 limiting toxicity 50 efficacy endpoints 50 dexamethasone Decadron 50 dosing 50 diarrhea predominant irritable 50 ACTEMRA 50 antiviral potency 50 LATUDA 50 octreotide LAR 50 IFN alpha 50 antifibrotic 50 Adlea 50 davunetide intranasal AL 50 Octreolin 50 investigational oral 50 Neuradiab 50 Clolar 50 IPX# 50 pharmacodynamic profiles 50 imatinib therapy 50 dosage regimen 50 long acting muscarinic 50 Spiegelmer ® 50 paricalcitol 50 docetaxel Taxotere 50 systemic antifungal 50 pyridostigmine 50 EDEMA3 50 Cloretazine R 50 sunitinib malate 50 continuous intravenous infusion 50 LB# [003] 50 dabigatran etexilate 50 AGILECT R 50 dosing frequency 50 estramustine 50 APD# 50 MyVax R 50 sitaxsentan 50 rapid virologic response 50 4mg/kg 50 tolevamer 50 Corlux 50 telbivudine 50 pitavastatin 50 prasterone 50 DASISION 50 Phase IIb 50 protease inhibitor 50 idraparinux 50 Phase Ia 50 PRECiSE 50 CK # administered 50 ASSERT trial 50 NPH insulin 49 alpha 2a 49 CK # 49 inecalcitol 49 tenofovir emtricitabine 49 pafuramidine 49 Initiated Phase 49 REOLYSIN ® 49 chronic HCV infection 49 radiolabeled 49 SYMMETRY trial 49 intravesical instillation 49 Bronchitol 49 cytostatic 49 ENBREL 49 HMG CoA reductase inhibitors 49 olaparib 49 IND enabling 49 Zenvia Phase III 49 cariprazine 49 bortezomib 49 EOquin 49 Nasulin 49 latrepirdine 49 masked placebo controlled 49 Tolerability 49 Cmax 49 FOLOTYN 49 Doxil ® 49 cell lymphoma CTCL 49 pain palliation 49 investigational compound